Dey et al., 2023 - Google Patents
Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccineDey et al., 2023
View PDF- Document ID
- 5091365078665422726
- Author
- Dey A
- Bhattacharya A
- Lonzarić J
- Burlak O
- Li J
- Upadhyay G
- Williams K
- Dong J
- Rohrer H
- Simon A
- Kuhlmann N
- Pustylnikov S
- Melo M
- Publication year
External Links
Snippet
Varicella zoster virus (VZV) is a highly contagious human herpes virus responsible for causing chickenpox (varicella) and shingles (herpes zoster). Despite the approval of a highly effective vaccine, Shingrix®, the global incidence of herpes zoster is increasing and …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roth et al. | A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice | |
| John et al. | Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity | |
| Chi et al. | DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice | |
| Jiaming et al. | The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection | |
| Pine et al. | Development of an mRNA-lipid nanoparticle vaccine against Lyme disease | |
| US20240226291A9 (en) | Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus | |
| TWI767275B (en) | Hiv vaccines and methods of making and using | |
| AU2018365296B2 (en) | A Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition | |
| Eberhardt et al. | Vaccination against a virus-encoded cytokine significantly restricts viral challenge | |
| Hensel et al. | Prophylactic herpes simplex virus 2 (HSV-2) vaccines adjuvanted with stable emulsion and toll-like receptor 9 agonist induce a robust HSV-2-specific cell-mediated immune response, protect against symptomatic disease, and reduce the latent viral reservoir | |
| CN103476788A (en) | Immunogenic chikungunya virus peptides | |
| Lassaunière et al. | Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2 | |
| Zuest et al. | Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice | |
| Kim et al. | Herpes zoster DNA vaccines with IL-7 and IL-33 molecular adjuvants elicit protective T cell immunity | |
| Sun et al. | Vaccine: X | |
| Bagley et al. | An interleukin 12 adjuvanted herpes simplex virus 2 DNA vaccine is more protective than a glycoprotein D subunit vaccine in a high-dose murine challenge model | |
| Yan et al. | CCL19 and CCL28 assist herpes simplex virus 2 glycoprotein D to induce protective systemic immunity against genital viral challenge | |
| Dey et al. | Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine | |
| Yang et al. | B602L-Fc fusion protein enhances the immunogenicity of the B602L protein of the African swine fever virus | |
| An et al. | Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19 | |
| Bhattacharya et al. | Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine | |
| KR20240135619A (en) | Boosting SARS-CoV-2 Immunity Using a Lentivirus-Based Nasal Vaccine | |
| Moliva et al. | Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates | |
| Swart et al. | Immunogenicity of an Ad26-based SARS-CoV-2 Omicron Vaccine in Naïve Mice and SARS-CoV-2 Spike Pre-immune Hamsters | |
| Le Grand et al. | High efficacy of VLA2001 vaccine against SARS-CoV-2 infection in non-human primates |